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Soluble immune markers in the 
different phases of chronic hepatitis 
B virus infection
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Heiner Wedemeyer1,2,7, Anke R. M. Kraft1,2, Christine S. falk2,6 & Markus cornberg1,2,8,9
Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are 
defined by virology as well as biochemical markers and differ in terms of prognosis and need for 
antiviral treatment. Currently, host responses reflected by immune markers are not considered in this 
definition. We aimed to study soluble immune markers and their distribution in different phases of 
chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble 
immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort 
of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared 
seroconverters to patients with unknown outcome. Significant differences were documented in the 
levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference 
among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients 
with hepatitis. TGF-β and IL-17 revealed different levels between HBeAg negative patients. HBeAg 
positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion 
compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, 
TGF-β and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.
Hepatitis B virus (HBV) is a global health burden with almost 250 million chronically infected people worldwide1. 
Chronic hepatitis B can lead to liver cirrhosis and hepatocellular carcinoma (HCC)2. The clinical courses differ 
remarkably from patient to patient and not all will develop cirrhosis and/or HCC. Therefore, early identification 
of patients with high risk of developing endpoints like cirrhosis and HCC is necessary, in order to define who is 
in need of close monitoring and/or antiviral treatment2.
Four phases of the natural course of chronic HBV infection are characterized, which are based on serologi-
cal and biochemical parameters2. The different phases of chronic HBV infection are not necessarily sequential. 
HBeAg-positive patients are usually young patients with very high HBV DNA titers. A differentiation between 
HBeAg-positive HBV infection (EPI) (formally called immune tolerance phase) and the HBeAg-positive hepatitis 
phase (EPH) is based on the occurrence of inflammatory signs such as elevated transaminases or histology-proven 
inflammation and/or clinical hepatitis2. After seroconversion to anti-HBe, HBeAg-negative patients with low 
HBV DNA level (<2,000 IU/mL) and no signs of liver inflammation are part of the HBeAg-negative infection 
(ENI) (formerly inactive carrier). HBeAg-negative patients with HBV DNA > 2,000 IU/ml and elevated ALT or 
liver inflammation due to immune escape mutations in the pre-core or basal core promoter are defined as having 
HBeAg-negative hepatitis (ENH).
Current clinical practice guidelines recommend antiviral treatment in patients with active hepatitis phases 
(EPH and ENH) but not in patients with HBeAg-positive or negative infection (EPI or ENI)2. However, a 
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proportion of patients with HBeAg-negative chronic HBV infection and persistently normal ALT level have HBV 
DNA levels between 2,000 and 20,000 IU/ml.
These patients are sometimes defined as grey-zone patients and some data suggest that these patients have no 
significant liver disease and no increased risk for disease progression3. However, long-term follow-up is impor-
tant to define the phase. Since quantitative HBV DNA and ALT levels may fluctuate in the natural course, the 
discrimination of patients with or without hepatitis is sometimes challenging2. In these cases, quantitative HBsAg 
as an additional serological parameter can be used to discern different phases of chronic HBV infection, e.g. ENI 
versus ENH4,5. However, additional markers are needed to improve our understanding of HBV pathogenesis. Due 
to the importance of immune responses in controlling the virus and finally resolving HBV infection, cytokines 
and chemokines might be a promising approach to further optimize the prediction of the natural course of 
chronic HBV infection. In patients infected with hepatitis C virus (HCV), several studies could show the impor-
tance of CXCL10 or also known as IP-10 (IFN-γ-inducible protein of 10 kD) in prediction of response in patients 
undergoing combination therapy of pegylated interferon α (PEG-IFN) and ribavirin6 or spontaneous clearance 
of acute HCV infection7. CXCL10 may also play an important role in HBV infection8, for example, CXCL10 
is up-regulated in the liver during acute HBV infection in chimpanzees9. In HBV/HCV co-infected patients, 
dominance of HCV was associated with higher CXCL10 and lower quantitative HBsAg levels10. In HBV patients 
undergoing therapy with PEG-IFN or nucleos(t)ide analogues (NA), high baseline CXCL10 level were associated 
with HBsAg decline during therapy11–14.
In this study, we assessed 14 soluble immune markers (SIM) including CXCL10 in different phases of chronic 
HBV infection in a large European cohort to identify additional immune marker, which should help to differen-
tiate the phases of chronic HBV infection.
Material and Methods
Patient population. Three hundred thirty-three European patients with persistent HBV infection, not 
undergoing antiviral therapy, were included in this cross-sectional study (Table 1).
Patients were recruited at the outpatient clinic of Hannover Medical School, Germany. One hundred 
thirty-four patients were HBeAg positive and 199 were HBeAg negative. They included 190 males and 143 
females with a median age of 32 years (min. 1, max. 69 yrs.). None of the included individuals were co-infected 
with hepatitis δ virus (HDV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV). Further exclu-
sion criteria were end-stage liver insufficiency, alcoholism, autoimmune disorders, immunosuppressive treatment 
and malignancies. Patients were divided according to their phase of chronic HBV infection or hepatitis defined 
according to EASL2:
•	 HBeAg-positive chronic infection (EPI, n = 45)
•	 HBeAg-positive chronic hepatitis (EPH, n = 89),
•	 HBeAg-negative chronic infection (ENI, n = 88)
•	 HBeAg-negative chronic hepatitis (ENH, n = 63)
•	 HBeAg-negative chronic infection, high replicative (HBV DNA > 20,000, ALT normal) (ENI-HR, n = 48).
The high replicative status in HBeAg negative chronic infection (ENI-HR) was assessed, when DNA levels 
were between 2,000 and 20,000 IU/mL in at least two consecutive time-points with ALT levels less or equal the 
upper limit of norm (ULN).
For a 2nd analysis a subpopulation of patients with chronic HBV infection (n = 39 out of 333) and patients 
with acute HBV (n = 10) infection or patients with suppressed HBV-DNA under nucleos(t)ide analogues (NA) 
therapy were included.
Serum HBsAg quantification. Abbott ARCHITECT assay (Abbott Diagnostics, Abbott Park, IL) was used 
to quantify serum HBsAg levels.
The dynamic range of the test is 0.05–250 IU/mL. Samples were diluted 1:100 in horse serum and if HBsAg 
levels were >250 IU/mL, samples were retested at a dilution of 1:500 and 1:1,000, respectively. Samples with 
HBsAg levels <0.05 IU/mL were retested without prior dilution. Results are given in IU/mL.
HBV-DNA measurement. Serum HBV-DNA was quantified by usage of COBAS AmpliPrep/COBAS TaqMan 
(Roche Diagnostics, Mannheim, Germany) and TaqMan Universal Master Mix (Applied Biosystems, Foster City, 
CA) with detection limits of 12 IU/mL and 50 IU/mL, respectively. HBV-DNA results are expressed in IU/mL.
HBV genotyping. HBV genotyping was assessed in 254 patients. DNA was extracted from 200 µL of serum 
using High Pure Viral Nucleic Acid K15it (Roche Diagnostics, Mannheim, Germany) according to the manu-
facturer’s protocol. HBV genotype was determined by a modified RFLP PCR assay with amplified HBV-DNA by 
use of a nested PCR as previous described15. The sequences abstracted were matched with the National Center 
for Biotechnology Information GenBank and compared with described HBV-prototypes (Accession No. for: 
HBV-A Z72478; HBV-B D00329; HBV-C X01587; HBV-D V01460; HBV-E X75658; HBV-G AF160501). The 
HBV S sequence and related references sequences were aligned with CLC Main Workbench 6 (CLCBio, Aarhus, 
Denmark). Genetic distance was estimated also by use of CLC Main Workbench 6. Bootstrap resampling and 
reconstruction were carried out 1,000 times.
Quantification of soluble immune mediators (cytokines and chemokines). The concentrations 
of following SIM were measured in sera/plasma using the Luminex-based multiplex technology. In all patients 
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CXCL10 (IP-10), IL-2, IL-4, IL-7, IL-10, IL-12p70 (IL-12), IL-16, IL-17, Interferon-γ, CCL4 (MIP-1β), TNF-α, 
TGF-β1, -2, -3 were measured and in the subpopulation additional concentrations were assessed for: IL-1β, IL-1R, 
IL-5, IL-6, IL-8, IL-9, IL-13, IL-15, Eotaxin, FGF-β2, G-CSF, GM-CSF, MCP-1, CCL3, PDGF-BB, RANTES, 
VEGF, IL-1α, IL-2Rα, IL-3, IL-12p40, IL-18, CTACK, GRO-α, HGF, IFN-α2, LIF, MCP-3, M-CSF, MIF, MIG, 
β-NGF, SCF, SCGF-β, SDF-1α, IL-2, TNF-β, TRAIL, sCDL40.
Bio-Plex assays (Bio-Rad, Hercules, USA) contain standard concentrations of each analyte and the calculation 
of respective standard curves allows for a precise definition of the concentrations of the protein of interest. The 
assay was performed according to the manufacturer’s protocol. In brief, lyophilized cytokine standard was resus-
pended in standard diluent. Serial dilution series were performed to generate standard curves for each cytokine, 
chemokine and growth factor of interest. The bead mixture, specific for cytokines, chemokines was incubated 
for 30 min at RT with 50 μL standard or serum samples that were diluted in sample diluent (1:2 dilution). Several 
washing steps were performed with 100 μL wash buffer/well, using the automated washer for magnetic beads 
(Bio-Rad). For the quantification of TGF-ß1-3, according to the manufacturer’s protocol, an acidification step 
was introduced by adding 5 µL HCl to the serum samples for 15 min in order to release TGF-ß from its binding 
proteins. After a normalization step with NaOH back to pH7, all samples were added to the bead mixture and 
processed with the same protocol like all other analytes. After addition of secondary biotinylated antibody mix for 
30 min at RT and three more washing steps, SAPE was added for 10 min at RT (1:100 dilution).
After three final washing steps, beads were resuspended with 125 μL assay buffer, acquired and analyzed by the 
BioPlex Manager 6.0 software.
In-vitro Peptide stimulation and intracellular staining (ICS). To study the effect of IL-12 on T cells, 
thawed PBMCs from two EPI patients were stimulated for 10 days with 2.5 µg/mL HBV core overlapping peptides 
(OLPs) (Genotype D, Proimmune, UK) in presence of 10 ng/ml rhIL-12 (Miltenyi Biotech). 41 HBV core OLPs 
were divided into 2 pools; HBV core peptides #1 including 20 peptides and HBV core peptides #2 including 
21 peptides. Cultures were supplemented with 5 U/ml rhIL-2 (Invitrogen Life Technologies) at days 4 and 8. 
Cells were restimulated at day 10 with the same HBV core OLPs and rhIL-12 for 6 hours. 2 µg/ml Brefeldin A 
(Sigma-Aldrich) was added after 1 hour of restimulation. For cell surface staining, PBMCs were stained with 
CD3 (Biolegend), CD14 (BD Bioscience), CD19 (BD Bioscience), CD4 (BD Bioscience) and CD8 (Biolegend). 
Dead cells were excluded using the Aqua cell stain kit (Life technologies). After fixation and permeabilization 
of PBMCs with Foxp3/Transcription Factor Staining Buffer Set (Ebioscience/Thermofisher), they were stained 
for IFN-γ (BD Bioscience) and TNF (Biolegend) for 30 min. Samples were acquired using BD LSR Fortessa (BD 
Biosciences) and data were analysed in FlowJo version 9.9.4 (Treestar).
Statistical analyses. Statistical analyses were performed by using SPSS software version 21 (SPSS Inc., 
Chicago, IL). P-values < 0.05 were considered as statistically significant. If not otherwise noted, all values men-
tioned are the median and 10–90% confidence interval. Correlation was tested with the Spearman correlation test.
A chi-square test was calculated for the comparison of discrete variables. For univariate analyses, we applied 
the Mann-Whitney U test for continuous data. Multivariate analyses were performed with the Kruskal-Wallis 
ANOVA. Multivariate logistic regression analyses were performed by using the likelihood ratio test for 
backward selection.
EPI (n = 45) HBV-
DNA ≥ 107 IU/ml, 
ALT < ULN*
EPH (n = 89) HBV-
DNA > 2,000 IU/ml, 
ALT ≥ 1.5ULN
ENI (n = 88) HBV-
DNA < 2,000 IU/ml, 
ALT < ULN
ENH (n = 63) HBV-
DNA ≥ 2,000 IU/ml, 
ALT ≥ 1.5ULN#
ENI-HR (n = 48)HBV-
DNA 2,000–20,000 IU/




Age, yrs (median, min.-max) 18 (1–49) 28 (7–68) 41 (12–69) 41 (22–67) 29 (14–63) <0.001
Gender, n (M/F) 25/20 66/23 40/48 41/22 18/30 <0.001
HBV DNA log10 IU/mL (median, 10–90% CI) 8.07 (7.75, 9.25) 8.04 (5.23, 8.98) 2.29 (1.08, 3.11) 5.56 (3.95, 8.01) 3.83 (3.39, 4.22) <0.001
HBsAg log10 IU/mL (median, 10–90% CI) 4.96 (4.34, 5.36) 4.31 (3.46, 5.16) 3.11 (0.87, 4.11) 3.91 (2.77, 4.39) 3.79 (3.05, 4.36) <0.001
HBV Genotype, n: 0.103
   A 2 23 14 14 5
   B 8 8 2 2 1
   C 2 5 1 3 0
   D 30 39 38 35 19
   E 0 1 0 1 0
   F 0 1 0 0 0
not performed 3 12 33 8 23
ALT (ULN) (median, 10–90% CI) 0.78 (0.53, 1.03*) 2.69 (1.59, 10.80) 0.65 (0.42, 0.92) 2.35 (1.39#, 11.69) 0.67 (0.43, 0.89) <0.001
Bilirubin (ULN) (median, 10–90% CI) 0.41 (0.19, 0.82) 0.53 (0.24, 1.34) 0.47 (0.29, 0.82) 0.73 (0.29, 1.20) 0.53 (0.28, 1.19) 0.038
Platelets, 106/µL (median, 10–90% CI) 242 (183, 335) 198 (127, 292) 220 (152, 298) 189 (103, 251) 224 (168, 286) <0.001
cirrhosis n (%) 1 (2.2) 12, (13,4) 10 (11.3) 6 (9.5) 2 (4.2) 0.301
Table 1. Baseline characteristics and factors univariately differentiating between patients in different phases of 
chronic HBV infection based on ANOVA (continuous values) and Chi-Square analysis (discrete values). *In EPI 
group patients with ALT < 1.5ULN were accepted if no inflammation in liver biopsy was observed. #In ENH group 
patients with ALT 1.0–1.5 ULN were accepted if significant inflammation (A1 > 2) in liver biopsy was observed.
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To prevent bias from different types of samples (sera/plasma), median values were calculated at first. The quo-
tient of median in plasma results divided by median in serum results was multiplied by each serum result for each 
cytokine. SIM concentrations were logarithmized (log10) in order to utilize parametric mathematics.
For analysis of cytokine patterns an outlier analysis was performed. For evaluation we used a 50-fold median 
threshold and a 1/50th median threshold in each group. All parameters, which were not located in this range, 
were deleted for the following analysis.
Ethical approval. This retrospective study was conducted in accordance with the guidelines of the 
Declaration of Helsinki, the principles of Good Clinical Practice and according to standards of the local ethics 
committee. All patients provided informed consent for the analysis of parameters assessed in stored blood sam-
ples taken during routine diagnostics. Data were analyzed anonymously. The local ethical committee of Hannover 
Medical School approved the retrospective, anonymous retesting of patient samples and the anonymous analysis 
of patient data.
Results
In this study 333 HBsAg positive patients were grouped in four consecutive phases of chronic HBV infection 
(EPI, EPH, ENI, ENH) and in the HBeAg-negative chronic infection with high replication (ENI-HR) (Table 1). 
HBeAg-positive patients (ENI and EPH) were significantly younger than patients with HBeAg-negative chronic 
HBV infection or hepatitis (EPI: 18.8 + 9.9, EPH: 32.4 + 16.0, ENI: 40.9 + 14.6, ENH: 40.8 + 11.2, p < 0.001, 
[years]). The proportion of females in ENI and ENI-HR was higher than in the EPH and ENH phases. HBV 
genotype distribution and prevalence of liver cirrhosis was similar between the different phases of chronic 
HBV-infection (Table 1).
Baseline characteristics of patients in the 2nd subpopulation with concentrations of 52 SIM are shown in 
Table S1.
Distribution of HBsAg levels. Serum HBsAg levels differed between the different phases in chronic hep-
atitis B patients (Fig. 1). Levels were highest in EPI patients (4.96 log10 IU/mL). In the EPH group the median 
HBsAg titer was 4.31 log10 IU/mL, whereas in ENI the lowest median HBsAg result was observed (3.11 log10 IU/
mL) (Fig. 1). Quantitative HBsAg (qHBsAg) data of the other two HBeAg negative phases (ENH and ENI-HR) 
compared with the results of EPH patients were more than 4.5- and 6.5-fold lower, respectively (3.91 log10 IU/
mL and 3.79 log10 IU/mL) (Fig. 1). Interestingly, there was no significant difference in qHBsAg results between 
ENH and ENI-HR (p = 0.754).
Distribution of cytokine and chemokine (soluble inflammatory marker) levels. Univariate 
ANOVA revealed several serological, biochemical and immunological parameters, which differed between the 
groups (Table 2; Fig. 2A).
For a better visualization a heat map showing expression patterns of SIM were created (Fig. 2B and 
Supplementary Fig. S1).
We have also tested the correlation between 14 cytokine levels and ALT and HBV DNA levels. We identi-
fied significant correlation between cytokine levels and ALT, especially in EPH and ENH, but weak correlation 
between expression levels and HBV DNA levels (Fig. 3A). CXCL10 concentrations showed the strongest correla-
tion to ALT titers in EPH (r = 0.53, p < 0.001) and ENH patients (r = 0.43, p < 0.001) (Fig. 3B).
In line with this data, CXCL10 showed the strongest signal among all SIM considering differentiation of HBV 
phases.
The highest CXCL10 concentrations were observed in the EPH and ENH patients with a median of 2.39 ± 0.36 
log10pg/mL and 2.38 ± 0.36 log10pg/mL, respectively. Significantly lower CXCL10 concentrations were docu-
mented in patients without hepatitis in the EPI- (2.04 ± 0.36 log10pg/mL; p < 0.001), ENI- (1.98 ± 0.32 log10pg/
mL; p < 0.001) or ENI-HR-phase (2.08 ± p0.19 log10pg/mL; p < 0.001) (Fig. 4A).
Among difficult-to-distinguish HBeAg negative individuals (ENI, ENH, ENI-HR) CXCL10, CCL4 (MIP-1β), 
IL-17, TGF-β1, -β2 and -β3, TNF-α, IL-12 (IL-12p70) and IL-16 differed significantly (Table 3) between these 
groups. CXCL10 concentrations were able to dissect ENH from ENI-HR and ENH from ENI, whereas IL-12 
helped to distinguish ENI and ENH. ENI patients had lower IL-12 and CCL4 levels (−0.73 ± 0.84 log10pg/mL 
and 1.18 ± 0.28 log10pg/mL) compared to ENH patients (−0.19 ± 0.90 log10pg/mL and 1.38 ± 0.35 log10pg/mL, 
Mann-Whitney U test; p < 0.001, respectively).
Interestingly, only TGF-β2 and IL-17 were useful to differentiate between ENI and ENI-HR.
In ENI individuals, median concentrations of TGF-β2 were 3.67 ± 0.14 log10pg/mL and thus higher than in 
patients classified to ENI-HR (3.57 ± R0.13 log10pg/mL; Mann-Whitney U test; p = 0.001). IL-17 levels were 
0.03 ± 0.43 log10pg/mL in ENI patients and −0.22 ± 0.42 log10pg/mL in ENI-HR patients; Mann-Whitney U test; 
(p = 0.040) (Fig. 4B). Performing a multivariate analysis only TGF-β remained an independent parameter for the 
differentiation of ENI- and ENI-HR patients (p < 0.001).
For an easier understanding, we restricted further analyzes to TGF-β2 when referring to TGF-β, based on 
the observed correlation between TGF-β1 and TGF-β2 (r = 0.79; p < 0.001) and between TGF-β3 and TGF-β2 
(r = 0.83; p < 0.001) (Figs S2a and S2b).
In a 2nd smaller cohort of chronic HBV patients with available data for 52 SIM, CXCL10 and TGF-β data 
were confirmed. In addition, sCD40L, PDGF-BB and RANTES differed between various phases of chronic HBV 
infection (Table S2).
SIM concentration patterns of patients with four phases of chronic HBV infection (EPI-HR not included) and 
SIM concentrations of acute hepatitis B patients, patients with HBV-DNA suppression and healthy individuals 
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are visualized in Fig. S3. Of note, CXCL10 values were high in patients with acute hepatitis B and low in healthy 
controls and NA treated patients with HBV suppression.
Cytokines in patients with HBeAg seroconversion. For 10 HBeAg positive patients with no history of 
antiviral therapy (n = 5 EPH and n = 5 EPI) a second time point after seroconversion to anti-HBeAg was available 
(Table S3). The mean range between both time points was 4 years and 8 months (range 12 months–84 months).
Comparing only those HBeAg seroconverters, who were considered as part of the EPI population before sero-
conversion with the other EPI patients with unknown outcome, higher IL-12 levels (−0.13 ± 0.54 log10pg/mL vs. 
−0.86 ± 1.05 log10pg/mL; p = 0.029) were documented (Fig. S4A). In addition, the seroconverters were younger 
than the rest of the EPI patients (6 ± 4 years vs. 20 ± 10 years; p = 0.008). After HBeAg seroconversion the values 
for TNF-α and ALT were lower than before in those patients (−0.31 ± 0.27 log10pg/mL vs. 0.34 ± 0.38 log10pg/
mL; p = 0.005 and 0.62 ± 0.13 ULN vs. 0.98 ± 0.19 ULN; p = 0.044).
Analyzes of HBeAg seroconverters formerly grouped to EPH phase showed no difference in cytokine values, 
HBsAg titers or levels of transaminases compared to patients in the EPH phase with no documented HBeAg sero-
conversion. When comparing HBeAg seroconverters classified as EPH patients before and after seroconversion, 
only IL-17 levels (0.47 ± 0.19 log10pg/mL vs. −0.28 ± 0.40 log10pg/mL; p = 0.032), showed significant differences.
Effect of IL-12 on T cell responses. To confirm the previously published data that IL-12 has an impact of 
HBV-specific T cell responses16, we have investigated the in-vitro effect of IL-12 on HBV core peptide stimulated 
PBMCs isolated from two young HBeAg positive patients with high HBsAg levels. After 10 days in-vitro HBV 
core peptide stimulation, CD4+, as well as CD8+ T cells, showed higher IFN-γ/TNF production assessed by an 
intracellular cytokine assay after IL-12 plus HBV core peptide re-stimulation compared with peptide stimulation 
only (Fig. S4B).
Figure 1. qHBsAg titers in chronic HBV. HBsAg titers in different phases of chronic HBV infection were 
quantified by using Abbott ARCHITECT assay (red: HBeAg positive, blue: HBeAg negative). Mann-Whitney U 
test was used for comparison of means.
Analyte P value Q Value Group
HBV DNA 5.42 × 10−120 4.35 × 10−119 ABCDEFGHIJ
HBsAg 1.47 × 10−37 5.89 × 10−36 ABCDEFGHI
CXCL10 5.80 × 10−18 1.16 × 10−17 ACEGHJ
Age 1.13 × 10−17 1.81 × 10−17 ABCDEFIJ
ALT 4.23 × 10−11 3.15 × 10−11 ACEGHJ
CCL4 1.18 × 10−8 6.31 × 10−9 EGHJ
IL-17 3.92 × 10−8 1.97 × 10−8 EGHJ
TGF-β2 3.93 × 10−7 1.86 × 10−7 DGIJ
TNF-α 7.85 × 10−4 2.86 × 10−4 CHJ
IL-12p70 2.58 × 10−3 8.12 × 10−4 EH
IL-16 2.83 × 10−3 8.74 × 10−4 CFHJ
IFN-γ 9.99 × 10−3 2.82 × 10−3 CH
Table 2. Evaluation of significant differences between different phases of chronic HBV patients by using 
Kruskal-Wallis ANOVA (A = EPI vs. EPH; B = EPI vs. ENI; C = EPI vs. ENH; D = EPH vs. ENI-HR; E = EPH vs. 
ENI; F = EPH vs. ENH; G = EPH vs. ENI-HR; H = ENI vs. ENH; I = ENI vs. ENI-HR; J = ENH vs. ENI-HR).
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Discussion
The differentiation of the phases of chronic HBV infection is important to individualize the management of 
the patients. However, a single determination of HBV DNA, as well as disease activity markers, does not allow 
an immediate classification to one of the phases. Quantitative HBsAg (qHBsAg) titers may help to improve the 
differentiation between phases in HBV infection4,5,17. Our results confirm data from previous studies that HBsAg 
Figure 2. SIM in phases of chronic HBV. (A) Significance evaluation of different virological, biochemical and 
immunological markers between phases of chronic HBV infection. The broken line indicates the significance 
threshold. Nonsignificant differences are marked with black dots. Significant differences are marked with a colored 
dot. Colored dots according to group color connotes significantly higher values of the parameter in this group 
compared to the other group. (B) Heat map showing the expression pattern of 14 soluble immune markers normalized 
by setting mean = 1 and variance = 0. The elements are colored according to the value of each SIM for each phase.
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Figure 3. Correlation of SIM and ALT or HBV DNA. (A) Spearman rank correlation coefficients between SIM 
levels (rows) and ALT (left panel) or HBV DNA (right panel). Red indicates a significant positive correlation, 
whereas blue indicates a significant negative correlation. White color indicates non-significant (n.s.). (B) 
Spearman rank correlation between CXCL-10 and ALT in EPH (left) and ENH patients (right).
Figure 4. CXCL10, TGF-β2 and IL-17 titers in different phases of chronic HBV infection. (A) CXCL10 levels in 
HBeAg-positive and HBeAg-negative phases of chronic HBV infection (B) TGF-β2 and IL-17 levels in HBeAg-
negative phases of chronic HBV infection. Mann-Whitney U test was used for comparison of means.
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levels differ between the phases of chronic HBV infection18,19. However, qHBsAg could not distinguish patients 
with ENH and patients with high replicative HBeAg negative infection (ENI-HR). Importantly, our study showed 
that soluble immune mediators could be a valuable additional tool to better characterize patients with chronic 
HBV infection including those with HBeAg negative infection.
Among 14 tested SIM, CXCL10 was the most significant SIM that helped to distinguish the different phases 
of chronic HBV infection. This was confirmed in a second smaller cohort. CXCL10 is known to be a mainly 
pro-inflammatory chemokine which has, among other functions, an impact in pathogenesis of chronic inflam-
matory in miscellaneous infectious diseases. CXCL10 may play a role in regulating activity for cell proliferation 
and induction of apoptosis20. This is an explanation why CXCL10 concentrations are highest in phases of active 
hepatitis and in patients with acute hepatitis B and, thus, may have an impact as an immunological imprint in the 
prognosis of the disease. High CXCL10 levels may suggest stronger immune activation, which can lead to disease 
progression21.
However, this may sometimes even be beneficial i.e. if these patients receive an additional treatment.
Several studies could show that higher CXCL10 levels were associated with HBsAg decline and HBeAg loss in 
response to pegylated Interferon alfa therapy and in patients undergoing antiviral therapy with nucleos(t)ide ana-
logues11–14,22. In HCV/HBV co-infected patients higher CXCL10 levels in HCV dominant patients were associated 
with lower HBsAg concentrations compared with HBV dominant patients or HBV mono-infected patients10. If 
HBV is controlled by immune responses, i.e. in inactive carriers (ENI), or in patients on NA therapy, CXCL10 
levels are low. In fact, in that case, lower CXCL10 levels may indicate that patients may clear HBsAg later on23. 
Thus, it is important to interpret the value of CXCL10 in the context of the different phases of HBV infection.
In the few patients analyzed longitudinally, CXCL10 was not significantly higher in patients who developed 
spontaneous HBeAg seroconversion compared with all HBeAg positive patients. This may suggest that CXCL10 
alone is not sufficient in this situation and as discussed above, additional antiviral therapy may be important. But 
interestingly, patients in the EPI phase who could experience HBeAg seroconversion had significantly higher 
levels of IL-12 than patients in the EPI phase with unknown follow-up. The number of patients tested is small, 
but IL-12 was described to have an impact in restoring Th1 T cell functions. Exhausted CD8+ T cells, which are 
present in chronic HBV infection and in part responsible for the persistence of HBV could gain their function-
ality back by induction of IL-1216. IL-12 is known to improve cytotoxicity, polyfunctionality and multispecificity 
of HBV-specific T cells. We could confirm the results shown by Schurich et al.16 that IL-12 could enhance the 
in-vitro HBV-specific T cell responses in two young HBeAg positive EPI patients. Thus, concepts to improve T 
cell responses including IL-12 induction may be considered for future immune therapies for chronic hepatitis B.
Importantly, patients with subsequent seroconversion were younger compared with those patients with 
unknown outcome. The higher IL-12 level in these young serooconverters suggests the presence of immune 
responses and is in line with recent data challenging the concept of immune tolerance in young patients with 
HBeAg positive infection24.
Another interesting result was the difference in transforming growth factor-beta (TGF-β) and IL-17 among 
HBeAg negative patients. ENI-HR patients had the lowest levels of TGF-β and IL-17. It has been shown that 
TGF-β is involved in the development of Th17 cells, which are the source of IL-1725. This is in line with our results 
that TGF-β correlates with IL-17. Under the induction of TGF-β CD4+ T cells may become regulatory T cells or 
Th17 cells, depending on other cytokines26. Th17 cells may contribute to HBV suppression but also inflamma-
tion. ENH patients show the highest level of TGF-β and IL-17 but due to other immune escape mechanisms this 
may not lead to HBV control. In this case Th17 T cells may contribute to immune activation and aggravation of 
chronic hepatitis B27,28. The Th17/IL-17 axis was described as fuel and flame of a sustained proinflammatory and 
profibrotic environment29.
This current study is one of the first larger cross-sectional studies with more than 300 patients presenting 
insights in different cytokine and chemokine levels in the different phases of chronic HBV infection. Limitations 
of this study were its retrospective design and in general a lack of follow-up data including clinical endpoints. The 
impact of the results was limited because this cross-sectional study provided no solid evidence to explain how the 
SIM influence disease progression and vice versa or if viral factors such as precore or BCP mutations influence the 
results. Prospective longitudinal studies following patients that switch the phases of chronic HBV infection are 
warranted to address this important question. In addition, the study in more than 300 patients was limited to only 
ENI (n = 88) ENH (n = 63) HRC (n = 48)
ANOVA 
p-value
CXCL10* 1.98 (1.68, 2.40) 2.38 (2.02, 2.87) 2.08 (1.82, 2.32) <0.001
CCL4* 1.18 (0.94, 1.55) 1.38 (1.08, 1.93) 1.22 (0.97, 1.50) <0.001
IL-17* 0.03 (−0.49, 0.48) 0.23 (−0.15, 0.72) −0.22 (−0.63, 0.34) <0.001
TGF-β1* 4.33 (4.01, 4.74) 4.46 (4.20, 5.08) 4.33 (4.03, 4.59) 0.002
TGF-β2* 3.67 (3.55, 3.77) 3.68 (3.60, 3.82) 3.57 (3.37, 3.72) <0.001
TGF-β3* 3.11 (2.77, 3.41) 3.14 (2.94, 3.49) 3.12 (2.59, 3.29) 0.007
TNF-α* 0.02 (−0.36, 0.60) 0.34 (−0.27, 1.64) 0.00 (−0.31, 0.76) <0.001
IL-12* −0.73 (−2.00, 0.23) −0.19 (−1.91, 0.84) −0.52 (−2.00, 0.24) 0.002
IL-16* 1.67 (1.32, 2.28) 1.88 (1.32, 2.87) 1.71 (1.26, 2.13) 0.001
Table 3. Significant differences of SIM concentrations in HBeAg negative phases of chronic HBV; Kruskal-
Wallis ANOVA. *log10 pg/mL (median, 10–90% CI).
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a small subset of SIM and we could not define thresholds for single SIM that could be used for clinical practice. 
Non-specific reasons for different SIM level cannot be excluded.
However, the results confirm that CXCL10 may have an important role in chronic HBV infection. In addition, 
IL-12 may be an interesting marker to predict HBeAg seroconversion in young patients with HBeAg positive 
infection and TGF-β/IL-17 could be helpful to further characterize HBeAg negative patients. Additional studies 
should investigate the role of immune marker in larger cohorts of patients with HBV infection.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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